Posts by: Margarida Azevedo

Margarida Azevedo

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

August 17, 2016August 17, 2016

Pulmonary Problems Can Plague Childhood Cancer Survivors Through Adult Life

Asthma, Emphysema, Idiopathic Pulmonary Fibrosis, News, Pneumonia

Pulmonary complications can mount in childhood survivors of cancer for as long as 25 years after initial diagnosis, and have a substantial impact on their daily life, a team of researchers ... Read more

July 8, 2016July 8, 2016

Nivalis Completes Enrollment in Phase 2 Study of Cystic Fibrosis Therapy

Cystic Fibrosis, News

Nivalis Therapeutics has enrolled the last patient in the larger of two Phase 2 clinical trials evaluating the company’s lead clinical candidate, N91115, for the treatment of cystic fibrosis patients with two faulty copies ... Read more

June 2, 2016June 2, 2016

Acute Respiratory Distress Syndrome Is Focus of $3M Research Grant

News, Pneumonia

Dr. David Dean at the University of Rochester Medical Center received a $3 million grant covering four years of research from the National Institutes of Health for the study and development ... Read more

May 27, 2016May 27, 2016

Severe Asthma Reduced in Phase 3 Benralizumab Tests

Asthma, News

AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound ... Read more

May 24, 2016May 24, 2016

First Patient Dosed in Phase 2 Trial of Potential CF Treatment

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., announced the first dosing of a cystic fibrosis (CF) patient enrolled in its second Phase 2 clinical trial evaluating the drug N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator ... Read more

May 20, 2016May 20, 2016

Positive Data on COPD Therapy Breo Ellipta SUMMIT Study Presented by GSK

COPD, News

GlaxoSmithKline (GSK) and Innoviva recently presented positive results from two analyses of the SUMMIT trial, which investigated the efficacy and safety of Breo Ellipta (fluticasone furoate/vilanterol, or FF/VI 100/25 mcg) in patients with chronic obstructive pulmonary disease (COPD) ... Read more

May 19, 2016May 19, 2016

Afferent Presents Promising Data from Phase 2 Study in People with Chronic Cough

Idiopathic Pulmonary Fibrosis, News

Afferent Pharmaceuticals announced positive results from a Phase 2 clinical trial of its candidate AF-219, a selective oral P2X3 antagonist, for the treatment of chronic cough. Data from the first cohort ... Read more

May 17, 2016May 17, 2016

Galapagos Initiates Phase 1 Study of GLPG2451 for Cystic Fibrosis

Cystic Fibrosis, News

Galapagos NV recently announced the initiation of a phase 1 study investigating its compound GLPG2451 for the treatment of cystic fibrosis (CF). The molecule is the second compound in Galapagos’ extended CF-portfolio to ... Read more

May 16, 2016May 16, 2016

AstraZeneca to Spotlight Respiratory Medicine ATS 2016

Asthma, COPD, News

The biopharmaceutical AstraZeneca recently announced key presentations set to spotlight its large respiratory disease medicines repertoire, during the American Thoracic Society (ATS) International Conference in San Francisco through May 18. The data ... Read more

May 13, 2016May 13, 2016

Theravance Poster to Show Phase 3 ATTAIN Trial Results on Pneumonia at ATS 2016

News, Pneumonia

Theravance Biopharma, Inc. recently announced in a press release the presentation of new data on VIBATIV® (telavancin), the company’s FDA-approved antibiotic, at the American Thoracic Society (ATS) 2016 International Conference, May 13-18 in San Francisco. The ... Read more